XENON PHARMACEUTICALS INC. (NASDAQ:XENE) Files An 8-K Results of Operations and Financial Condition

On January 8, 2018, Xenon Pharmaceuticals Inc. (the “Company”) announced via press release key milestones for 2018 and certain financial information as of December31, 2017. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in Items 2.02 and 7.01 of this Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.

(d) Exhibits.

to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:

Xenon Pharmaceuticals Inc. ExhibitEX-99.1 2 xene-ex991_7.htm EX-99.1 xene-ex991_7.htm Exhibit 99.1 NEWS RELEASE   Xenon Pharmaceuticals Outlines Key Milestones for 2018   BURNABY,…To view the full exhibit click here
About XENON PHARMACEUTICALS INC. (NASDAQ:XENE)
Xenon Pharmaceuticals Inc. (Xenon) is a biopharmaceutical company discovering and developing a pipeline of differentiated therapeutics for orphan indications. The Company’s platform, Extreme Genetics, enables the discovery of validated drug targets by studying rare human diseases with extreme traits, including diseases caused by mutations in ion channels (channelopathies). Extreme Genetics involves the study of families where individuals exhibit inherited severe traits, or phenotypes. Its integrated platform includes in-house capabilities for human genetics, small molecule drug discovery, as well as preclinical and clinical development. Its pharmaceutical partners include Teva Pharmaceutical Industries, Ltd. (Teva), Genentech, Inc. (Genentech) and Merck & Co., Inc. (Merck). Extreme Genetics discovery platform has yielded the first approved gene therapy product in the European Union, or the EU, and a development pipeline, including Glybera, TV-45070, GDC-0276 and GDC-0310, and XEN801.